John F. Paolini - Sep 1, 2022 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
CHIEF MEDICAL OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol
KNSA
Transactions as of
Sep 1, 2022
Transactions value $
-$5,800
Form type
4
Date filed
9/6/2022, 04:10 PM
Previous filing
Apr 11, 2022
Next filing
Nov 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise +1.73K +4.91% 36.8K Sep 2, 2022 Direct F1
transaction KNSA Class A Common Share Tax liability -$5.8K -507 -1.38% $11.44 36.3K Sep 2, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Share Option Award $0 +59.9K $0.00 59.9K Sep 1, 2022 Class A Common Share 59.9K $11.97 Direct F2
transaction KNSA Restricted Share Unit Award $0 +9.99K $0.00 9.99K Sep 1, 2022 Class A Common Share 9.99K Direct F1, F3
transaction KNSA Restricted Share Unit Options Exercise $0 -1.73K -25% $0.00 5.18K Sep 2, 2022 Class A Common Share 1.73K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022.
F3 The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
F4 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021.